Jia Jun-di, Li Yu-Feng, Xiao Min, Jiang Xu, Xiu Sheng-Yao, Wang Jie
Dongzhimen Hospital,Beijing University of Chinese Medicine Beijing 100700,China.
Zhongguo Zhong Yao Za Zhi. 2021 Mar;46(5):1260-1267. doi: 10.19540/j.cnki.cjcmm.20200702.502.
To systematically evaluate the efficacy and safety of Ningxinbao Capsules in treatment of arrhythmia by Meta-analysis. Randomized controlled trial(RCT) or quasi-randomized control trial(Quasi-RCT) on Ningxinbao Capsules treating arrhythmia were obtained by computer-based retrieval in CNKI, Wanfang, VIP, SinoMed, PubMed, Web of Science, Cochrane Library and EMbase as well as manual retrieval, with time limit from database establishment to April 7, 2020. According to the inclusion and exclusion criteria of trials, all RCTs were screened and evaluated. Then the effective data were collected and RevMan 5.3 Meta-analysis software was used for analysis. Thirteen trials were included, involving 1 379 patients in total. Ningxinbao Capsules combined with anti-arrhythmia Western medicine were adopted as the intervention, and the patients in control group were treated with the anti-arrhythmia Western medicine alone. Meta-analysis results showed that as compared to control group, Ningxinbao Capsules combined with anti-arrhythmia Western medicine group was superior in clinical efficacy, dynamic electrocardiogram and average heart rate in patients with bradycardia, with indicated statistically significant differences. Ningxinbao Capsules had fewer adverse reactions and could relieve the toxic and side effects of anti-arrhythmia medicine possibly. The study showed that Ningxinbao Capsules played a role in treatment of arrhythmia and was relatively safe. However, due to the limited quality of the included studies, high-quality clinical trials are needed to verify the conclusions.
通过Meta分析系统评价宁心宝胶囊治疗心律失常的有效性和安全性。通过计算机检索中国知网、万方、维普、中国生物医学文献数据库、PubMed、Web of Science、Cochrane图书馆和EMbase，以及手工检索，获取关于宁心宝胶囊治疗心律失常的随机对照试验（RCT）或半随机对照试验（Quasi-RCT），检索时间范围为各数据库建库至2020年4月7日。根据试验的纳入和排除标准，对所有RCT进行筛选和评价。然后收集有效数据，采用RevMan 5.3软件进行Meta分析。共纳入13项试验，涉及1379例患者。干预措施采用宁心宝胶囊联合抗心律失常西药，对照组患者仅接受抗心律失常西药治疗。Meta分析结果显示，与对照组相比，宁心宝胶囊联合抗心律失常西药组在临床疗效、动态心电图及缓慢性心律失常患者的平均心率方面更优，差异有统计学意义。宁心宝胶囊不良反应较少，可能减轻抗心律失常药物的毒副作用。研究表明，宁心宝胶囊在心律失常治疗中发挥作用且相对安全。然而，由于纳入研究质量有限，需要高质量的临床试验来验证结论。
